Pictet Asset Management (UK)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Pictet Asset Management (UK)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-33,706	Closed	-$1.41M	–	1858
2021 Q1	$1.41M	Sell	33,706 -5,300	-14%	-$246K	﹤0.01%	1008
2020 Q4	$1.82M	Sell	39,006 -2,200	-5%	-$103K	﹤0.01%	967
2020 Q3	$1.75M	Sell	41,206 -25,083	-38%	-$1.1M	﹤0.01%	906
2020 Q2	$3.18M	Sell	66,289 -18,181	-22%	-$907K	0.01%	793
2020 Q1	$3.89M	Buy	84,470 +29,600	+54%	+$1.49M	0.01%	708
2019 Q4	$3.3M	Sell	54,870 -2,700	-5%	-$161K	0.01%	849
2019 Q3	$3.26M	Sell	57,570 -9,482	-14%	-$533K	0.01%	794
2019 Q2	$3.73M	Sell	67,052 -33,348	-33%	-$1.74M	0.01%	765
2019 Q1	$5.07M	Buy	100,400 +33,500	+50%	+$1.49M	0.01%	695
2018 Q4	$2.69K	Buy	66,900 +21,000	+46%	+$1.08M	0.01%	790
2018 Q3	$3.18M	Sell	45,900 -5,700	-11%	-$432K	0.01%	834
2018 Q2	$3.9M	Sell	51,600 -8,100	-14%	-$510K	0.01%	714
2018 Q1	$3.15M	Buy	59,700 +29,400	+97%	+$1.71M	0.01%	744
2017 Q4	$1.62M	Sell	30,300 -900	-3%	-$50.1K	﹤0.01%	812
2017 Q3	$1.86M	Buy	+31,200	New	+$1.89M	0.01%	796

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management (UK)'s EGRX Position: Q2 2021 in Review

Pictet Asset Management (UK) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 33,706 shares — an estimated $1.41M sold.

Pictet Asset Management (UK) first reported a position in EGRX in Q3 2017 and held it in 15 quarters. The position peaked at $5.07M in Q1 2019. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

Pictet Asset Management (UK) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Pictet Asset Management (UK) sold 33,706 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.41M.
Pictet Asset Management (UK) first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 15 quarters.
Pictet Asset Management (UK)'s Eagle Pharmaceuticals, Inc. position peaked at $5.07M in Q1 2019.
146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.